The FGF-3 (Fibroblast growth factor 3) gene was found to be located at the second known common integration site for Mouse Mammary Tumor Virus (MMTV) (Peters et al., 1983; Dickson et al., 1984; Peters et al., 1984) . The MMTV does not possess a viral oncogene and transforms cells by activation of a cellular protooncogene in the vicinity of the proviral integration site. The FGF-3 gene was thought to be a candidate gene for proviral activation in malignant transformation of the breast. The gene was initially termed INT-2.
Both the genomic sequence of the FGF-3 gene as well as the amino acid sequence of the predicted protein revealed a high homology to the sequences of the acidic and basic fibroblast growth factors (Dickson & Peters, 1987) . The human homologue of FGF-3 has been mapped to chromosome 1 lql3 Moore et al., 1986) . Although the relevance of FGF-3 to human carcinogenesis had not been demonstrated various observations in mammary tumours had suggested that FGF-3 is a proliferation marker (Adnane et al., 1989; Liderau et al., 1988) . It was described that amplification of FGF-3 correlated with steroid receptor levels, recurrence and lymph node status in mammary carcinoma (Liderau et al., 1988; Adnane et al., 1989) . In addition, two other genes, PRADI and EMS1 (Schuuring et al., 1992) , have been described recently which are also located on chromosome llql3. They were found to be coamplified with FGF-3, HSTF1 and BCL1 in 40 breast and squamous cell carcinomas as well as nine cell lines. PRADI and EMS1 overexpression was found to correlate with amplification (Schuuring et al., 1992 (Day et al., 1975 (Sambrook et al., 1989 (5'TGGTCTCCTTAAACCTGTCTT3') were used for the Pglobin gene as published previously (Saiki et al., 1987) . These oligonucleotides yielded a 168 bp PCR product. Primers FGF3a (5'CAGAAGCAGAGCCCGGATAA3') and FGF3b (5'ACGCCAAGATGTCGCCAGGA3') were designed by a computer programme (Rychlik & Rhoads, 1989 Brown and Benedetti (Brown & Benedetti, 1977 (Kaplan & Meier, 1958; Mantel, 1966 Table I .
Tumour samples with less than 1.5 copies were defined as not amplified and classified as single copy tumours, whereas tumour samples with more than 1.5 copies were defined as amplified (Figure 1) receptor levels could be estimated (Table II No significant association of overall survival with FGF-3 amplification was found (Figure 2) .
Discussion
This study provides the first evidence of the amplification of the FGF-3 oncogene in patients with ovarian cancer. In breast cancer the FGF-3 oncogene seems to be one of the three most frequently amplified oncogenes (Adnane et al., 1989) . Amplification frequencies have been reported to range between 4% and 23% of cases of mammary carcinoma (Varley et al., 1988; Zhou et al., 1989) . In the present study on ovarian cancer the FGF-3 gene was found to be amplified in a similar percentage of cases, since 20% of the ovarian cancer samples investigated were found to have an amplified FGF-3 oncogene.
Prognostically favourable groups could benefit from the presence of a single copy of the FGF-3 gene, because all FIGO stage I, all GO and 88% of the cases with no residual tumour had a single copy number. Except for the association of FIGO stage with FGF-3 copy number (P = 0.008) no other correlations between FGF-3 amplification and clinicopathological indices could be found. In addition, no influence of FGF-3 copy number on overall survival was noted. This could at least partly be explained by the small patient numbers in this investigation.
CA 125 is a tumour antigen, which was reported by Bast et al. in 1983 , and its validity as a prognostic factor was subsequently confirmed (Sevelda et al., 1987; Sevelda et al., 1989; Rosen et al., 1990; Sevelda et al., 1991) . Significant correlation between CA 125 and the classical prognostic factors such as residual tumour mass, histological grading, ascites and FIGO stage was reported recently (Makar et al., 1992) . These parameters characterise the biologic properties of a tumour. No correlation (P = 0.06) between preoperative CA 125 serum levels and FGF-3 amplification could be observed in the present investigation. The borderline association between CA 125 and FGF-3 amplification as well as the significant correlation between FIGO stage and oncogene amplification combine to suggest that FGF-3 could contribute to aggressiveness and tumour proliferation. Larger numbers of patients should however be investigated to support this notion. In addition, levels of FGF-3 expression in ovarian tumours with and without 1 1q13 amplification should be studied in order to shed light on the possible role of FGF-3 as a proliferation marker. 
